The tenth item of the comprehensive product information summary, "pharmaceutical particulars," deals not with the properties of the drug itself but with how it behaves as a finished formulation: how stable it stays during storage, and what changes occur when it is mixed with other drugs, infusion fluids, or solvents. This is not a place to talk about efficacy, the way the clinical results or pharmacology sections do. What clinicians want here is something more basic. Can this drug be safely added to a drip? Does it discolor at room temperature? The unglamorous information that bears directly on day-to-day handling is the star of this section.
The discipline governing this section is among the clearest in the entire guide. Only "facts confirmed by testing" may be written. No evaluation, no endorsement, no reassurance of safety belongs here. Why such restraint? The reason becomes visible when you trace it back to the spirit of the foreword.
01What this section covers — stability and compatibility
Two broad categories may be recorded under pharmaceutical particulars. One is the stability of the formulation. The other is its compatibility, the changes that occur when it is combined with other drugs. In both cases, the basis is limited to test results. Not conjecture or generalities, but results actually observed under defined conditions, presented exactly as observed.
Stability information forms the foundation for judging "for how long and under what environment" the drug can be used. Compatibility information gives the reader the material to decide for themselves, at the infusion line or the point of admixture, whether a given combination should be avoided. Neither is a place for the company to hand down a conclusion. State the facts, and leave the judgment to healthcare professionals. That is the basic stance.
It is no accident that "stability" and "compatibility" share one section. Both are physicochemical behaviors that only become an issue once the product is actually being handled. Before the question of whether it works comes the question of whether it can be handled safely and appropriately. The structure of the section embodies that order.
02Compatibility data must state the conditions and the counterpart
When compatibility test results are included, two things must always be made clear: the test conditions, and the names of the products examined.
Why are the conditions required? Compatibility outcomes change with temperature, concentration, time, pH, and light. If the conditions are hidden and only "no change" is written, the reader may wrongly conclude the drug is safe under any circumstance. In reality, only a certain temperature and a certain duration were verified. Adding the conditions is the act of correctly handing the reader the reach of the test: how far it guarantees, and from where it is unverified.
Specifying the products examined rests on the same thinking. Rather than lumping things together as "the such-and-such injection," show concretely which product was mixed. As discussed below, even when the active ingredient is identical, behavior can differ if the excipients differ.
Why "no change" without conditions is hazardous
Suppose a compatibility test with a certain drug was run up to 25°C for six hours, and no change was seen in appearance or content. If this is displayed merely as "no compatibility change," it leads the reader to picture safety even at 24 hours, or under high temperature. This is not a lie: there genuinely was no change up to 25°C and six hours. Yet the manner of presentation grants reassurance beyond the facts. The foreword's principle, that the duty not to deceive and the duty not to mislead are distinct, is made concrete right here.
"No change" is not an unconditional declaration of safety. It is only an observation within the conditions verified by testing. A display that omits the conditions is a textbook case of being factually correct yet misleading.
03Results are limited to the "facts" of physicochemical change — no evaluative words
What may be written as a compatibility result is limited to the facts of physical and chemical change. The color changed, a precipitate formed, the content declined, no abnormality was seen in appearance — such observed facts may be written. But evaluative words such as "compatible" or "may be combined" cannot be used.
This line is one of the strictest prohibitions in the guide, and the reason runs deep. The moment "may be combined" is written, the meaning shifts from a report of observed fact to permission or recommendation for use by the company. Pharmaceutical particulars is not a place to approve efficacy or usage. The foreword's logic of "complementation," that the summary cannot exceed the approved content by even a single character, is at work here too. Whether two drugs may be combined is a clinical judgment that varies with conditions, patient, and route of administration, and must not be pre-empted by a display in this section.
| What may be written (facts) | What may not be written (evaluation/judgment) |
|---|---|
| No change was observed in appearance or color | "May be combined" |
| A white precipitate formed | "Compatible" |
| Content declined by ○% after six hours | "Can be co-administered without problem" |
| pH shifted from ○ to ○ | "Can be safely admixed" |
Why a line is drawn between fact and evaluation
As a matter of scientific practice, observation (the data) and interpretation (the conclusion) sit on different layers. From the same data, the conclusion can differ depending on who interprets it and in what situation. The guide bars evaluative words to prevent the company from stepping into the interpretive layer and steering the reader's judgment. The "fairness and objectivity" that the basic considerations of Chapter 1 consistently demand, and the stance of "not leading toward a convenient conclusion," are concentrated in this small prohibition.
04Choosing the counterpart drug — consistency, contraindication, caution
There is discipline, too, in choosing which drug's compatibility test to present. The drug used as the counterpart must be consistent with the product's dosage and administration and with its precautionary information. Lining up test results for combinations that are not actually expected in practice, or that contradict the precautionary information, only confuses the field further.
A particularly weighty prohibition is this: do not include compatibility test results with drugs that are contraindicated for concomitant use. A contraindicated combination is one defined in the precautionary information as one that "must not be used together." Placing compatibility data for such a drug in the summary, even as the physicochemical fact of "no change," would supply a false context suggesting the two might be combined. The display of the section must not conflict with contraindication, the highest-order safety provision.
Do not include compatibility test results with contraindicated-combination drugs. Being physicochemically stable and being clinically permissible to combine are matters of entirely different dimensions. Contraindication is a clinical judgment; compatibility change is a physicochemical observation. No display may conflate the two.
For caution-combination drugs, note that fact alongside
For drugs that fall short of contraindication but require caution in concomitant use, including compatibility test results is not itself denied. However, the fact that the drug is subject to caution for concomitant use must be noted alongside. Even if no physicochemical change was seen, the information that caution is clinically required must not be left stranded outside the section. The fact of the compatibility change and the separate axis of cautionary information must be made joinable in the reader's own hands. This too is an implementation of the duty "not to mislead."
05Relationship to the standalone compatibility table
The compatibility content within pharmaceutical particulars is often expanded into a separate resource, the "compatibility change table." The two are run on continuous principles. In the compatibility table as well, the test conditions and the products examined must be stated, and results are confined to the facts of physicochemical change, with no evaluative words such as "compatible/incompatible."
If anything, the compatibility table demands these points more concretely: that even when the active ingredient is identical, other companies' products be recorded by trade name in view of excipient effects; that compatibility data with contraindicated-combination drugs not be included; and that caution-combination drugs be noted as such. The pharmaceutical particulars section is also the entry point that leads to this more detailed resource.
Even with the same active ingredient, compatibility behavior can differ if the excipients differ — which is exactly why one does not generalize to "the such-and-such injection" but identifies, at the level of trade name, which product was tested. Generalization is the tempting shortcut, but it is the source of misunderstanding. Holding fast to specifics is what sustains the integrity of this section.
06Connection to the spirit of the foreword
Pharmaceutical particulars may look like a plain section, far removed from showy claims of efficacy. Yet it is also where the design philosophy of the guide appears most plainly. Show only the facts and add no evaluation; state the conditions and the counterpart so as not to misrepresent the reach; do not conflict with contraindication, the higher-order provision. Each of these converges on a single point: the product information summary is a "complement" to the package insert and does not exceed the approved content.
Hand over the information needed to handle the drug safely and appropriately, with neither exaggeration nor omission. Before speaking of efficacy, first make it possible to handle the drug correctly. What this section embodies is the very order that runs through the whole guide: a tool for using the drug safely comes before a tool for selling it.
The pharmaceutical particulars section is where stability and compatibility are presented plainly as "facts confirmed by testing." In compatibility testing, state the conditions and the products examined, keep the results to the facts of physicochemical change, and use no evaluative words such as "compatible" or "may be combined."
Make the counterpart drugs consistent with dosage and precautionary information; do not include compatibility test results with contraindicated-combination drugs; and note caution-combination drugs as such. Physicochemical stability and clinical permissibility of combination are different dimensions, and no display may conflate them.
Barring evaluative words while requiring the conditions and the counterpart to be stated is an implementation, at the level of field-handling information, of the foreword's duty "not merely to avoid falsehood but to avoid misleading," and of the logic of "complementation" that never exceeds the approved content.